Background Isatuximab is a monoclonal antibody that binds a specific epitope on the human
CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous …

Background Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies
has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone…

1Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation
Trust, Bristol, 2Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, …

Nonmyeloablative conditioning is increasingly used for transplantation in a wide range of
diseases, but little is known about its impact on the incidence of infections and immune …

A nonmyeloablative conditioning regimen was investigated in 47 patients with hematological
malignancy receiving allogeneic progenitor cells from matched, unrelated donors. The …

Background Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed
CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory …

Background Isatuximab is an anti-CD38 monoclonal antibody approved in combination with
pomalidomide–dexamethasone and carfilzomib–dexamethasone for relapsed or refractory …

This Policy Review presents the International Myeloma Working Group's clinical practice
recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the …

In November 2014 the International Myeloma Working Group ( IMWG ) revised the definition
of multiple myeloma, such that asymptomatic patients with newly diagnosed multiple …

With increasing number of therapies available for the treatment of multiple myeloma, it is
timely to examine the course of patients' journeys. We investigated patient characteristics, …